Generics companies to move away from "little white pills"
Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.
In an increasingly competitive market, it is widely accepted that generics companies are facing enormous downward pricing pressure. The mix of new product opportunities is changing, innovators are devising stronger defensive strategies, and the regulatory burden is becoming more expensive.
Drawing from his recent White Paper, "Generics companies, responding to tough times, steer towards higher-risk portfolio strategies", Brandon Boyd of Clarivate Analytics outlined the various portfolio strategies open to generics companies and their uptake to a packed audience at CPHI Worldwide in Madrid. Common to all was a willingness to accept higher levels of risk.
First, serving new channels such as hospitals and even government programs leads to demands on a whole range of factors from packaging through to final documentation. Second, enhancing entry strategies with patent challenges offers the extremely high risk/reward option compared with waiting for patent expiry. Third, moving up the product value chain from oral solids ("little white pills") to injectables and drug-device combinations, while appealing, often requires entering complex partnerships or M&As with all the attached unknowns.
As examples of this he pointed to the case of generic Advair, which still hasn’t been approved despite repeated attempts and generic Copaxone which, while approved with multiple players, still seems a risky area.
So, will generics companies take these risks? The answer according to Boyd appears to be 'yes' – in particular, Indian and Chinese companies are taking some or even all three of the above options. He concluded that meeting the challenge to differentiate will dominate the sector for the foreseeable future and that only those with patience, an unswerving focus on quality and execution will survive.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance